Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from DBV Technologies SA – American ( (DBVT) ) is now available.
On September 5, 2025, DBV Technologies announced the establishment of an at-the-market (ATM) equity offering program on Nasdaq, allowing the company to sell up to $150 million in American Depositary Shares (ADS) through Citizens JMP Securities. The proceeds from this program are intended to support the Biologics License Application for the VIASKIN Peanut patch and other corporate purposes, with the sales being conducted at market prices and subject to regulatory limits.
The most recent analyst rating on (DBVT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on DBV Technologies SA – American stock, see the DBVT Stock Forecast page.
Spark’s Take on DBVT Stock
According to Spark, TipRanks’ AI Analyst, DBVT is a Neutral.
DBV Technologies SA’s overall score is primarily impacted by financial instability and weak technical indicators. The positive corporate event provides some optimism, but significant financial and operational challenges remain. The stock’s valuation is unattractive due to unprofitability and lack of dividends.
To see Spark’s full report on DBVT stock, click here.
More about DBV Technologies SA – American
DBV Technologies is a clinical-stage biopharmaceutical company focused on developing innovative products for the treatment of food allergies. The company is known for its proprietary technology platform, VIASKIN, which is used to develop product candidates, including the VIASKIN Peanut patch for toddlers aged 1-3 years old.
Average Trading Volume: 30,423
Technical Sentiment Signal: Buy
Current Market Cap: $250.8M
See more data about DBVT stock on TipRanks’ Stock Analysis page.